Short- and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease

Journal of Invasive Cardiology

Volumn 19, Issue 8, 2007, Pages 331-337

  Mishkel, Gregory J ^a,b,c   Varghese, Joji J ^c   Moore, Anna L ^b   Aguirre, Frank ^a,b,c   Markwell, Stephen J ^c   Shelton, Marc ^a,b,c  

^a ST JOHN'S HOSPITAL   (United States)

^b Prairie Education and Research Cooperative   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RENAL REPLACEMENT THERAPY; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME;

AGED; CORONARY DISEASE; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SIROLIMUS; STENTS; SURVIVAL ANALYSIS; THROMBOSIS;

EID: 34548106537     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. United States Renal Data System 2005 Annual Data Report. Am J Kidney Dis 2006;47:S174-S184.
2. Gupta R, Birnbaum Y, Uretsy, BF. The renal patient with coronary artery disease: Current concepts and dilemmas. J Am Coll Cardiol 2004;44:1343-1353.
3. Anavekar NS, McMurray JJV, Velazques, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
4. Reddan DN, Szczech L, Bhapkar MV, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial Transplant 2005;20:2105-2112.
5. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300-305.
6. Best PJ, Berger PB, Davis BR, et al for the PRESTO Investigators. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: Results from the PRESTO trial. J Am Coll Cardiol 2004;44:1786-1791.
7. Le Feuvre C, Borentain M, Beygui F, et al. Comparison of short- and long-term outcomes of coronary angioplasty in patients with and without diabetes mellitus and with and without hemodialysis. Am J Cardiol 2003;92:721-725.
8. 〈http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4253b1_01. pdf〉 last accessed January 29, 2007.
9. Morice MC, Serruys PW, Sousa JE, et al for the RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-1780.
10. Moses JW, Leon MB, Popma JJ, et al for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
11. Colombo A, Drzewiecki J, Banning A, et al for the TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
12. Stone GW, Ellis SG, Cox DA, et al for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
13. Daemen J, Lemos P, Aoki J, et al. Treatment of coronary artery disease in dialysis patients with sirolimus-eluting stents: 1-year clinical follow-up of a consecutive series of cases. J Invasive Cardiol 2004;16:685-687.
14. Halkin A, Mehran R, Casey CW, et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: Results from the TAXUS-IV trial. Am Heart J 2005;150:1163-1170.
15. Lemos PA, Arampatzis CA, Hoye A, et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol 2005;95:167-172.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S246.
18. «http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4253b1_01. pdf» Last accessed April 24, 2006.
19. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006;296:1377-1384.
20. Das P, Moliterno DJ, Charnigo R, et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol 2006;18:405-408.
21. Kuchulakanti PK, Torguson R, Chu WW, et al. Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2006;97:792-797.
22. Hassani SE, Chu WW, Wolfram RM, et al. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. J Invasive Cardiol 2006;18:273-277.
23. Halkin A, Selzer F, Marroquin O, et al. Clinical outcomes following percutaneous intervention with drug-eluting vs. bare-metal stents in dialysis patients. J Invasive Cardiol 2006;18:577-583.
24. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
25. Schrier RW. Role of diminished renal function in cardiovascular mortality: Marker or pathogenetic factor? J Am Coll Cardiol 2006;47:1-8.
26. Menon V, Sarnak MJ. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: A high-risk combination. Am J Kidney Dis 2005;45:223-232.
27. Weiner DE, Tabatabai, S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: Exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006;48:392-401.
28. Keane WF. Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 2001;38:1372-1375.